Unformatted text preview: ers or the
products of combinatorial chemistry) and
high-throughput screening to advance
understanding of biological pathways and
to identify compounds that act as positive
or negative regulators of individual gene
products, pathways or cellular phenotypes.
Although the pharmaceutical industry
applies this approach widely as the first step
in drug development, few academic investigators have access to this methodology or are
familiar with its use.
Providing such access more broadly,
through one or more centralized facilities,
could lead to the discovery of a host of useful
probes for biological pathways that would
serve as new reagents for basic research
and/or starting points for the development
of new therapeutic agents (the ‘hits’ from
such library screens will generally require
medicinal chemistry modifications to yield
therapeutically usable compounds).
Also needed are new, more powerful
technologies for generating deep molecular
libraries, especially ones tagged to allow the
ready determination of precise molecular
targets. A centralized database of screening
results should lead to further important
View Full Document
This document was uploaded on 04/02/2014.
- Fall '14
- The Tempest